- Home
- QGEN vs AXSM Comparison
QGEN vs AXSM Comparison
Compare QGEN & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QGEN | AXSM |
|---|---|---|
| Founded | 1986 | 2012 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 9.0B |
| IPO Year | 1996 | 2015 |
Fundamental Metrics
Financial Performance| Metric | QGEN | AXSM |
|---|---|---|
| Price | $50.85 | $182.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 20 |
| Target Price | $51.30 | ★ $197.95 |
| AVG Volume (30 Days) | ★ 3.6M | 634.4K |
| Earning Date | 02-04-2026 | 02-23-2026 |
| Dividend Yield | ★ 4.72% | N/A |
| EPS Growth | ★ 409.76 | N/A |
| EPS | ★ 2.04 | N/A |
| Revenue | ★ $2,089,999,000.00 | $561,263,000.00 |
| Revenue This Year | $7.75 | $67.77 |
| Revenue Next Year | $6.13 | $58.56 |
| P/E Ratio | $25.00 | ★ N/A |
| Revenue Growth | 5.65 | ★ 65.83 |
| 52 Week Low | $39.61 | $86.99 |
| 52 Week High | $57.82 | $191.50 |
Technical Indicators
Market Signals| Indicator | QGEN | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 51.67 | 56.93 |
| Support Level | $50.53 | $181.00 |
| Resistance Level | $51.71 | $187.18 |
| Average True Range (ATR) | 1.27 | 5.09 |
| MACD | -0.47 | -1.30 |
| Stochastic Oscillator | 24.69 | 43.75 |
Price Performance
Historical ComparisonAbout QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.